Protagonist Therapeutics (PTGX) Cash from Investing Activities (2015 - 2026)

Protagonist Therapeutics (PTGX) has 12 years of Cash from Investing Activities data on file, last reported at $90.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 196.28% year-over-year to $90.9 million; the trailing twelve-month figure through Mar 2026 stood at $136.0 million (up 133.99% YoY), and the FY2025 full-year result was -$49.3 million, up 83.53% from the prior year.
• Cash from Investing Activities grew to $90.9 million in Q1 2026, from $48.8 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $90.9 million in Q1 2026 to a low of -$208.7 million in Q3 2024.
• A 5-year average of -$12.1 million and a median of $3.9 million in 2022 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities slumped 1657.48% in 2023 and jumped 659.48% in 2025, its largest moves.
• Tracing PTGX's Cash from Investing Activities over 5 years: stood at $3.9 million in 2022, then tumbled by 1657.48% to -$61.3 million in 2023, then soared by 85.76% to -$8.7 million in 2024, then jumped by 659.48% to $48.8 million in 2025, then soared by 86.2% to $90.9 million in 2026.
• Business Quant data shows PTGX's Cash from Investing Activities at $90.9 million in Q1 2026, $48.8 million in Q4 2025, and -$58.6 million in Q3 2025.